NO20084857L - HPV-16-basert papillomavirus vaksine - Google Patents

HPV-16-basert papillomavirus vaksine

Info

Publication number
NO20084857L
NO20084857L NO20084857A NO20084857A NO20084857L NO 20084857 L NO20084857 L NO 20084857L NO 20084857 A NO20084857 A NO 20084857A NO 20084857 A NO20084857 A NO 20084857A NO 20084857 L NO20084857 L NO 20084857L
Authority
NO
Norway
Prior art keywords
hpv
preventing
treating
papillomavirus vaccine
papillomavirus
Prior art date
Application number
NO20084857A
Other languages
English (en)
Inventor
Ronald Rooke
Stephane Paul
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of NO20084857L publication Critical patent/NO20084857L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelsen av en sammensetning som innbefatter et eller flere tidlig polipeptider til human papillomavirus (HPV)- I 6 eller en nukleinsyre som koder et eller flere tidlig polypeptider til HPV- I 6 for fremstilling av et medikament for hindring eller behandling av en infeksjon eller en patologisk tilstand forårsaket av minst et papillomavirus forskjellig fra HPV- I 6. Oppfinnelsen har svært særlig interesse innenfor immunoterapi, særlig ved hindring eller behandling av HPV persistente infeksjoner som kan føre til cervikal intraepitel neoplasi (CIN) og til slutt til cervikal kreft.
NO20084857A 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine NO20084857L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360014 2006-04-21
PCT/EP2007/003368 WO2007121895A2 (en) 2006-04-21 2007-04-17 Hpv-16-based papillomavirus vaccine

Publications (1)

Publication Number Publication Date
NO20084857L true NO20084857L (no) 2008-11-18

Family

ID=38362856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084857A NO20084857L (no) 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine

Country Status (13)

Country Link
US (1) US20100061957A1 (no)
EP (1) EP2013230A2 (no)
JP (1) JP2009534332A (no)
KR (1) KR20090005011A (no)
CN (1) CN101426811A (no)
AU (1) AU2007241406A1 (no)
BR (1) BRPI0710238A2 (no)
CA (1) CA2649392A1 (no)
IL (1) IL193661A0 (no)
MX (1) MX2008013488A (no)
NO (1) NO20084857L (no)
RU (1) RU2008145712A (no)
WO (1) WO2007121895A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
RU2530555C2 (ru) 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
EP2239330A1 (en) 2009-04-07 2010-10-13 Institut Pasteur Neuron generation, regeneration and protection
EP2593548A4 (en) * 2010-07-15 2013-11-27 British Columbia Cancer Agency ANTIGEN E7 COMPOSITIONS OF HUMAN PAPILLOMAVIRUS AND USES THEREOF
CN102343103B (zh) * 2011-07-26 2016-04-27 马丁 人乳头状瘤病毒16型三肽疫苗的筛选和验证及持续表达hpv16 e5, e6, e7的肿瘤动物模型的构建
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
US9214855B2 (en) 2013-05-03 2015-12-15 Cooper Technologies Company Active power factor correction circuit for a constant current power converter
US9548794B2 (en) 2013-05-03 2017-01-17 Cooper Technologies Company Power factor correction for constant current input with power line communication
US9190901B2 (en) 2013-05-03 2015-11-17 Cooper Technologies Company Bridgeless boost power factor correction circuit for constant current input
US9000736B2 (en) 2013-05-03 2015-04-07 Cooper Technologies Company Power factor correction algorithm for arbitrary input waveform
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2019517522A (ja) * 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法
KR20190073416A (ko) * 2016-10-05 2019-06-26 피디에스 바이오테크놀러지 코퍼레이션 신규한 hpv16 hla-비제한적 t-세포 백신, 조성물 및 이의 사용 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
EP1425039A4 (en) * 2001-03-23 2005-02-02 Us Gov Health & Human Serv PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS
ATE465753T1 (de) * 2002-10-21 2010-05-15 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden

Also Published As

Publication number Publication date
CN101426811A (zh) 2009-05-06
WO2007121895A3 (en) 2008-03-20
KR20090005011A (ko) 2009-01-12
IL193661A0 (en) 2011-08-01
JP2009534332A (ja) 2009-09-24
WO2007121895A2 (en) 2007-11-01
US20100061957A1 (en) 2010-03-11
RU2008145712A (ru) 2010-05-27
EP2013230A2 (en) 2009-01-14
MX2008013488A (es) 2008-10-30
CA2649392A1 (en) 2007-11-01
BRPI0710238A2 (pt) 2011-08-09
AU2007241406A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
NO20084857L (no) HPV-16-basert papillomavirus vaksine
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
MY150855A (en) Oral compositions containing extracts of zizyphus joazeiro and related methods
NO20092360L (no) Nye antiproliferasjonsantistoffer
EP2336174B8 (en) Human monoclonal antibodies against Hendra and Nipah viruses
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
MX2009011865A (es) Tratamiento de lesiones viralmente inducidas.
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
MX337932B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
IL176522A0 (en) Universal amplification of fragmented rna
ECSP055869A (es) Vacuna hpv-16 y -18 l1 vlp
MY150604A (en) 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
BR112018011310A2 (pt) mutante da proteína l1 do papilomavírus humano tipo 58
NO20081014L (no) Sammensetninger
EA201000329A1 (ru) Циклические депсипептиды
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
NO20070980L (no) Selekterte kondenserte heterocykler og anvendelser derav
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
NO20080650L (no) Forbindelser omfattende DMXAA for behandling av kreft
CL2009000791A1 (es) Compuestos derivados de labirintopeptina; procedimiento para prepararlos que comprende fermentar la cepa actinomadura namibiensis (dsm 6313); uso de los compuestos para tratar infecciones bacterianas, infecciones viricas y/o dolor; composicion farmaceutica que los comprenden; dna que codifica la preprolabirintopeptina a2.
WO2009120022A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
WO2007059356A3 (en) Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application